Latest Financial Position News

Robex Resources confirms steady progress on its Kiniero Gold Project in Guinea, maintaining schedule and budget for first gold production in late 2025.

Euroz Hartleys Group Limited has announced a proposed $23 million capital return to shareholders, pending approval at a July 2025 meeting, aiming to streamline its corporate structure while maintaining financial strength.

Western Gold Resources has voluntarily suspended its shares from trading as it prepares to disclose details of a significant agreement and respond to an ASX price query.

Empire Energy Group has successfully closed and upsized its Share Purchase Plan to $7 million, raising crucial funds to advance its Beetaloo Basin projects. The capital raise strengthens the company’s cash position ahead of key operational milestones.

BetMakers Technology Group has successfully raised $11.5 million through a share placement aimed at repaying debt and funding strategic growth initiatives, including a potential acquisition in Nevada.

Alvo Minerals Limited has had its trading suspension lifted immediately following the release of details about its Entitlement Offer, signaling renewed market activity.

Lindian Resources has secured a combined $1.65 million cash inflow from the exercise of unlisted options and a government R&D tax refund, strengthening its financial position for advancing the Kangankunde Rare Earths Project.

Norwood Systems has successfully delivered a crucial software milestone under a major telecom contract, while also reporting strong customer receipts that bolster its cash position.

North Stawell Minerals has announced a combined $3.6 million capital raise through a placement and a pro-rata entitlement offer, aiming to bolster its exploration activities without materially altering company control.

EVT Limited has officially kicked off the sale process for its prime Sydney CBD property at 525 George Street, offering a rare mixed-use development opportunity with significant growth potential.

Perseus Mining outlines a robust five-year gold production plan targeting up to 2.7 million ounces with stable costs and strong cash margins, backed by major projects in Africa.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.